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Abstract 
Matrix γ-carboxyglutamic acid protein (MGP) is a vitamin K-dependent protein playing a pivotal role in 
preventing arterial calcification. In the present study, we aimed to investigate the relation between three 
single nucleotide polymorphisms of MGP gene and ischemic stroke (IS) in the Ukrainian population. 170 IS 
patients and 124 healthy controls were recruited to the study. MGP SNPs were examined by PCR-RFLP 
methodology. The distribution of homozygous carriers of the major allelic variant, and heterozygous and 
homozygous minor allele variants of the T-138C MGP promoter polymorphism (rs1800802) in patients with 
IS was 61.2%, 31.2% and 7.6%, respectively. The corresponding distributions of the variants in the control 
group were 59.7%, 35.6%, 4.8%. With regard to the G-7A promoter polymorphism (rs1800801), the 
respective distributions were 35.9%, 48.8% and 15.3%, compared to 43.5%, 50% and 6.5% in the control 
group. Finally, the respective distributions according to the Thr83Ala exon 4 polymorphism (rs4236) were 
39.4%, 48.8% and 11.8%, compared to 34.7%, 53.2% and 12.1% in the control group. Using logistic 
regression analysis, it was estimated that A/A genotype (G-7A polymorphism) was significantly (P=0.016) 
associated with IS (OR=2.943; 95% CI: 1.218–7.109) in the Ukrainian population. A-allele homozygotes of 
female sex had a risk of IS more than 7 times higher compared with carriers of G/G genotype. 
Keywords: Matrix Gla protein, single nucleotide polymorphism, ischemic stroke, arterial calcification, 
Ukrainian population. 
Ukrayna popülasyonunda iskemik inme hastalarında MGP promotör ve ekzon 4 
polimorfizminin araştırılması  
Özet 
Matris γ–karboksiglutamik asit proteini (MGP) vitamin-K bağımlı protein olup arteriyal kalsitleşmeyi 
önlemede önemli rol oynar. Bu çalışmada, MGP geninin üç tek nükleotit polimorfizmi (TNP) ile Ukrayna 
popülasyonunda iskemik inme (İİ) arasındaki ilişkiyi araştırmayı hedefledik. Çalışmaya 170 İİ hastası ve 124 
sağlıklı kontrol katıldı. MGP TNP’leri PCR-RFLP metodolojisi ile test edildi. İH hastalarında T-138C MGP 
promoter polimorfizminin (rs1800802) majör alel varyantının homozigot taşıyıcılarının ve heterozigot ve 
homozigot minör alel varyantlarının dağılımları sırası ile, %61.2, %31.2 ve %7.6’dır.  Kontrol grubunda ilgili 
varyant dağılımları %59.7, %35.6 ve %4.8’dir. G-7A promoter polimorfizminde (rs1800801) ise ilgili 
dağılımlar %43.5, %50 ve %6.5 olan  kontrol grubu ile karşılaştırıldığında %35.9, %48.8 ve %15.3’dir.  Son 
olarak, Thr83Ala ekzon 4 polimorfizmine (rs4236) göre dağılımlar %34.7, %53.2 ve %12.1 olan kontrol 
grubu ile karşılaştırıldığında %39.4, %48.8 ve %11.8’dir. Lojistik regresyon analizi kullanarak, Ukrayna 
popülasyonunda İİ ile A/A genotipinin (G-7A polimorfizmi) anlamlı (P=0.016) olarak ilişkili olduğu 
(OR=2.943; 95% CI: 1.218–7.109) tahmin edilmiştir.  
Anahtar kelimeler: Matris Gla protein, tek nükleotid polimorfizmi, iskemik inme, arteriyal kalsifikasyon, 
Ukrayna popülasyonu.
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Introduction 
Ischemic stroke (IS) is, in many instances, the 
consequence of a thrombus forming on a ruptured 
atherosclerotic plaque. Extracellular matrix 
calcification is considered to be a novel marker of 
atherosclerosis and related to both coronary artery 
and cerebrovascular disease. It has been shown that 
arterial calcification in major vessel beds is 
associated with vascular brain disease (Bos et al., 
2011).  
Recent studies suggest that in addition to 
modifiable risk factors, such as hypertension, 
hyperlipidemia, and cigarette smoking, there is a 
strong genetic component to the development of 
arterial calcification. For instance, the heritability 
of the presence of coronary artery calcification has 
been estimated to be up to 50% (Post et al., 2007).   
Key genes known to be involved in the 
regulation of the complex process of ectopic soft 
tissue mineralization are those acting as 
calcification inhibitors such as matrix γ-
carboxyglutamic acid protein (MGP), osteocalcin 
(BGP), osteoprotegerin (Opg), and fetuin (Abedin 
et al., 2004; Doherty et al., 2004; Giachelli, 2004;  
Guzman, 2007; Weissen-Plenz et al., 2008). 
Among those, MGP, a vitamin K-dependent 
protein, is widely accepted as playing a pivotal role 
in preventing local mineralization of the vascular 
wall (Luo et al., 1997; Schurgers et al., 2005; 
Proudfoot and Shanahan, 2006). It has been shown 
that the anticalcifying activity of MGP depends 
upon the γ-carboxylation of specific glutamic acid 
(Glu) residues in MGP. This vitamin K-dependent 
reaction yields γ-carboxyglutamic acid (Gla) 
residues, which are then able to bind calcium 
(Murshed et al., 2004). 
The human MGP gene is located on 
chromosome 12p (Cancela et al., 1990). Among the 
large number of identified MGP single nucleotide 
polymorphisms (SNPs) eight are under the most 
intensive investigation: two SNPs are located in 
exons, and six in the upstream region of the MGP 
gene. In vitro studies suggest that SNPs in MGP are 
associated with altered promoter activity 
(Herrmann et al., 2000; Farzaneh-Far et al., 2001; 
Kobayashi et al., 2004). In addition, there is some 
evidence that MGP SNPs are associated with 
arterial calcification (Herrmann et al., 2000; 
Brancaccio et al., 2005; Crosier et al., 2009), 
although these results are not consistent (Kobayashi 
et al., 2004; Taylor et al., 2005). 
There are a large number of studies in which the 
association of varies gene polymorphisms with IS 
has been investigated (Kubo, 2008; Debette and 
Seshadri, 2009; Matarin et al., 2009; Wang et al., 
2009; Low et al., 2011), but only in one of them the 
MGP SNPs were a subject of interest (del Rio-
Espinola et al., 2010).  
The purpose of the present study was to 
investigate the association of three MGP SNPs (T-
138C, G-7A, Thr83Ala) with IS in the Ukrainian 
population. 
Materials and methods 
Study groups 
The study recruited 170 IS patients (57,6% men 
and 42,4% women) 40 to 85 years of age (mean age 
[± SE] 64,7±0,7) admitted to Sumy Clinical 
Hospital No.5. A final diagnosis of IS was 
established on the basis of clinical, computed 
tomography and magnetic resonance imaging 
examinations. Each case of IS was assessed 
according to TOAST criteria (Adams et al., 1993).  
The patients with IS of cardioembolic origin and 
undetermined etiology were excluded from the 
study group. The control group consisted of 124 
clinically healthy individuals with the absence of 
cardio- and cerebrovascular pathologies, as 
confirmed by medical history, ECG, and 
measurement of arterial pressure and biochemical 
data. The study had been previously approved by 
the Ethic Committee of the Medical Institute of 
Sumy State University. Appropriate informed 
consent was obtained from all patients and control 
subjects. The participants were unrelated Ukrainian 
people from the northeastern region of Ukraine. 
Blood sampling for genotyping was performed 
under sterile conditions into 2.7 ml tubes (S-
Monovette [Sarstedt, Germany]) containing EDTA 
potassium salt as an anticoagulant, samples were 
frozen and stored at -20ºC.  
Genotyping of SNPs 
DNA for genotyping was extracted from the venous 
blood using commercially available kits (Isogene 
Lab Ltd, Russia) according to the manufacturer’s 
protocol. To identify MGP SNPs the polymerase 
chain reaction (PCR) with subsequent restriction 
fragment length polymorphism (RFLP) analysis 
was performed as previously described (Garbuzova 
et al., 2012). Briefly, specific regions of the MGP 
gene were amplified using pairs of specific primers.  
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For T-138C polymorphism (rs1800802) they 
were (F) 5`-
AAGCATACGАТGGCCAAAACTTCTGCA-3` 
and (R) 5`-
GAACTAGCAТТGGAACTTTTCCCAACC-3`; 
for G-7A polymorphism (rs1800801):  (F) 5`-
CTAGTTCAGTGCCAACCCTTCCCCACC-3` 
and (R) 5`-
TAGCAGCAGTAGGGAGAGAGGCTCCCA-3`; 
for Thr83Ala polymorphism (rs4236): (F) 5`-
TCAATAGGGAAGCCTGTGATG-3` and  (R) 5`-
AGGGGGATACAAAATCAGGTG -3`. PCR 
products were digested using restriction enzymes: 
BseNI (for T-138C), NcoI (for G-7A), and Eco477 
(for Thr83Ala). The restriction fragments were 
separated by electrophoresis and analysed on an 
ethidium bromide-stained 2.5% agarose gel 
visualized using ultraviolet transillumination. 
Statistical analysis 
Using the Pearson χ2 test, allelic frequencies in 
healthy controls and IS patients were found to be in 
Hardy-Weinberg equilibrium. Statistical analysis 
was performed to assess the independent main and 
joint effects of all analyzed SNPs. To detect the 
strongest main effect of three MGP SNPs the 
logistic regression method was applied by using 
SPSS 17.0. A comparison of variables between the 
IS subgroups was performed using ANOVA. 
Differences were considered statistically significant 
with a P-value < 0.05. 
Results 
Genotypes of three studied MGP polymorphisms 
are summarized in Table 1. As shown,  major allele 
homozygous and heterozygous, and minor allele 
homozygous T-138C polymorphisms of the MGP 
promoter were detected in 61.2%, 31.2% and 7.6% 
of the IS group, respectively (control group: 59.7, 
35.5% and 4.8%). Analysis of the G-7A promoter 
polymorphism yielded respective figures of 35.9%, 
48.8% and 15.3% (control group: 43.5%, 50% and 
6.5%). The distribution of genotypes when 
analyzing Thr83Ala polymorphism (exon 4) was 
39.4%, 48.8% and 11.8% in IS group (control 
group: 34.7%, 53.2% and 12.1).  
Promoter T-138C Promoter G-7A Exon 4 Thr83Ala 
Genotype Control group 
(n=124) 
IS group 
(n=170) 
Control group 
(n=124) 
IS group 
(n=170) 
Control group 
(n=124) 
IS group 
(n=170) 
AA 74 (59.7) 104 (61.2) 54 (43.5) 61 (35.9) 43 (34.7) 67 (39.4) 
Aa 44 (35.5) 53 (31.2) 62 (50.0) 83 (48.8) 66 (53.2) 83 (48.8) 
aa 6 (4.8) 13 (7.6) 8 (6.5) 26 (15.3) 15 (12.1) 20 (11.8) 
 
The differences in the distribution of allelic 
variants between the control and IS groups were 
close to the level of statistical significance only for 
the G-7A promoter polymorphism (P=0,051). In 
women, but not in men, the differences between G-
7A genotypes frequency in IS and controls were 
significant as shown in Table 2.  
Using logistic regression analysis (Table 3), it 
was estimated that A/A genotype (G-7A 
polymorphism) was significantly (P=0.016) 
associated with IS (OR=2.943; 95% CI, 1.218 – 
7.109). Respective analysis for male and female 
subjects is presented in Table 4. Women who were 
minor A-allele homozygotes had a risk of IS more 
then 7 times higher compared with female carriers 
of G/G genotype. 
Some clinical characteristics of IS patients with 
various MGP genotypes are presented in Table 5. 
There were no differences in the studied parameters 
between major allele homozygotes, heterozygotes, 
and minor allele homozygotes for all three 
polymorphisms (with the exception of sex 
distribution for G-7A polymorphism). 
 
 
 
 
 
 
Table 1. Genotypes of MGP polymorphisms in patients with ischemic stroke (IS) and control subjects.  Data 
presented as n (%). A – major allele; a – minor allele 
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Table 2.  Genotypes of G-7A MGP promoter polymorphism in female and male patients with ischemic 
stroke (IS) and control subjects.  Data presented as n (%). 
 
 
 
 
 
 
 
Table 3. Results of logistic regression analysis of association between MGP polymorphisms and ischemic 
stroke.Homozygotes by major allele were considered as a reference group. SE – standard error, OR – odds 
ratio, CI – confidential interval 
SNP Genotype Coefficient of 
regression SE 
Wald 
statistic 
P-
value OR 
%95 CI 
Lower 
%95 CI 
Upper 
T/C -0.186 0.258 0.521 0.470 0.830 0.500 1.377 Promoter 
T-138C C/C 0.382 0.526 0.527 0.468 1.465 0.522 4.107 
G/A 0.193 0.253 0.584 0.445 1.213 0.739 1.991 Promoter 
G-7A A/A 1.079 0.450 5.752 0.016 2.943 1.218 7.109 
Thr/Ala -0.235 0.259 0.824 0.364 0.790 0.476 1.313 Exon 4 
Thr83Ala Ala/Ala -0.265 0.402 0.435 0.510 0.767 0.349 1.687 
 
Discussion 
Arterial calcification is an abnormal process that 
can greatly increase morbidity and mortality (Lehto 
et al., 1996). MGP is considered one of the most 
relevant physiological inhibitors of soft tissue 
mineralization known today. In mice, targeted 
deletion of the MGP gene causes extensive 
calcification of the elastic lamellae of the 
abdominal aorta (Luo et al., 1997). Extensive 
vascular calcification is also induced when γ-
carboxylation of MGP is inhibited using the 
vitamin K-antagonist, warfarin (Price et al., 1998). 
In the present study, we explored association 
between genetic variation in the MGP gene and the 
risk of IS development. Analysing MGP SNPs, we 
found the G-7A promoter polymorphism to be 
associated with IS in Ukrainian population. We did 
not revealed statistically significant relation 
between the other two studied polymorphisms (T-
138C, Thr83Ala) and IS.  
Published data on the MGP SNPs association 
with MGP serum concentration and artery 
calcification, and the consequences of 
atherosclerosis (myocardial infarction in 
particularly) are contradictory.   
Farzaneh et al. (2001) did not find any 
relationship between the G-7A polymorphism and  
serum MGP level in healthy persons (Netherlands), 
but did detect the significant association of T-138C 
polymorphism with above-mentioned parameter. 
The highest level of serum MGP was revealed in 
the C/C homozygotes and the lowest one – in T/T 
homozygotes.    
In contrast to the above study, Crosier et al. 
(2009) found no association of the T-138C 
polymorphism with serum MGP concentration, but 
they showed a significant relationship between the 
other two polymorphisms (G-7A, Tht83Ala) and 
serum MGP levels in the healthy men and women 
(USA). In minor allele homozygotes, the serum 
MGP concentration was the lowest, in major allele 
homozygotes the highest, in heterozygotes the 
intermediate values were registered.  
In the same study, it was shown that all three 
MGP SNPs (T-138C, G-7A, Thr83Ala) are related 
to the coronary artery calcification (CAC) in men, 
but not in women (Crosier et al., 2009).  
 
Women Men 
Genotype 
Control IS Control IS 
G/G 18 (40.0) 21 (29.2) 36 (45.6) 40 (40.8) 
G/A 25 (55.6) 34 (47.2) 37 (46.8) 49 (50.0) 
A/A 2 (4.4) 17 (23.6) 6 (7.6) 9 (9.2) 
Total 45  72  79  98  
P-value 0.022 0.798 
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Table 4. Logistic regression analysis of association between G-7A MGP promoter polymorphism and 
ischemic stroke in male and female subjects. OR – odds ratio, CI – confidential interval 
Sex Allele OR (CI) P-value 
Women A/A vs. G/G 7.286 (1.479-35.895) 0.015 
 G/A vs. G/G 1.166 (0.516-2.632) 0.712 
Men A/A vs. G/G 1.350 (0.437-4.166) 0.602 
 G/A vs. G/G 1.192 (0.641-2.217) 0.579 
Table 5. Clinical characteristics of ischemic stroke patients with respect to genotypes. Data are mean ± SE.  
 A/A A/a a/a P 
T-138C polymorphism 
n 104 53 13  
Age, years 65.4±0.92 63.0±1.39 64.7±2.13 0.288 
Gender, M/F 58/46 35/18 5/8 0.162* 
BMI (M), kg/m2 27.8±0.56 27.4±0.64 28.1±1.22 0.862 
BMI (F), kg/m2 29.1±0.74 29.4±0.93 29.0±1.17 0.789 
Systolic BP, mmHg 168±2.9 165±3.6 168±9.8 0.780 
Diastolic BP, mmHg 96±1.7 94±1.8 93±3.8 0.628 
Fasting glucose, mmol/L 5.9±0.15 5.9±0.2 6.1±0.53 0.916 
G-7A polymorphism 
n 61 83 26  
Age, years 63.0±1.15 65.3±1.04 66.8±2.09 0.164 
Gender, M/F 40/21 49/34 9/17 0.026* 
BMI (M), kg/m2 27.2±0.45 27.9±0.68 28.6±1.53 0.536 
BMI (F), kg/m2 28.3±0.8 29.9±0.86 28.2±1.13 0.315 
Systolic BP, mmHg 167±3.7 167±3.3 167±5.2 0.996 
Diastolic BP, mmHg 97±2.0 94±1.8 97±2.4 0.593 
Fasting glucose, mmol/L 5.8±0.18 6.0±0.17 6.2±0.35 0.481 
Thr83Ala polymorphism 
n 67 83 20  
Age, years 65.1±1.2 64.4±1.0 64.7±2.1 0.912 
Gender, M/F 44/23 45/38 9/11 0.176* 
BMI (M), kg/m2 27.6±0.47 27.6±0.67 28.3±1.9 0.891 
BMI (F), kg/m2 29.4±0.84 28.6±0.78 29.9±1.53 0.668 
Systolic BP, mmHg 163±3.7 171±3.0 163±6.6 0.252 
Diastolic BP, mmHg 95±1.8 96±1.7 95±4.4 0.812 
Fasting glucose, mmol/L 5.9±0.2 6.0±0.17 5.9±0.3 0.859 
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In some studies, MGP polymorphisms were 
also shown to be associated with arterial 
calcification and myocardial infarction (MI)  
(Herrmann et al., 2000; Brancaccio et al., 2005), 
while in others (Kobayashi et al., 2004; Taylor et 
al., 2005) no association between MGP SNPs and 
cardiovascular events was found. Moreover, in the 
studies in which such associations were reported, 
the relationship between the type of MGP 
polymorphism and arterial calcification was 
different. For example, in the AXA study, the 
minor alleles -7A and 83Ala were associated with 
increased femoral artery calcification (Herrmann et 
al., 2000), while in the above-mentioned study by 
Crosier et al. (2009), the same alleles were linked 
to a decreased level of CAC.    
It should be noted that the majority of studies 
cited here was devoted to the relation of MGP to 
CAC and MI. As to cerebral artery atherosclerosis 
and its severe events such as IS, the role of arterial 
calcification in this disease and the association of 
MGP with cerebrovascular pathology were the 
subject of investigation and discussion only in a 
few publications. In particular, Bos et al. (2011) 
established a close relationship between 
calcification in the various vessel beds outside the 
brain and imaging markers of vascular brain 
disease.  Calcification in each vessel bed was 
shown to be associated with the presence of 
cerebral infarcts and with larger volume of white 
matter lesions (WMLs). The most prominent 
associations were found between the intracranial 
carotid calcification and WML volume and 
between the extracranial carotid calcification and 
infarcts.   
Acar et al. (2012) studied a relationship of 
serum MGP levels to the development of 
intracerebral hemorrhages (ICH) and found that in 
patients with ICH, serum MGP concentration was 
much lower than in control group. Moreover, in the 
non-survivors, the serum MGP levels were 
statistically significantly lower in comparison to the 
survivors. According to the authors, measurement 
of this parameter may be of value to estimate 
mortality.   
At present, there are only a few publications 
concerning relation of the MGP SNPs to 
cerebrovascular disease. Analysing 236 
polymorphisms, del Rio-Espinola et al. (2010) 
showed that only two of them (G-7A of MGP and 
T-1C of CD40) were related to the brain vessel 
reocclusion after fibrinolysis in IS patients. In our 
study, it was shown that the G-7A polymorphism of 
MGP was associated with IS. In our previous 
investigation (Harbusova et al., 2011), this variant 
of the MGP promoter polymorphism was found to 
be in association with the acute coronary syndrome 
(ACS). Minor allele homozygotes (A/A) had 
significantly higher risk of ACS as well as IS.  This 
could means that there are some common 
mechanisms of pathogenesis in both ACS and IS 
concerning to MGP. Those may be atherosclerosis, 
arterial calcification, and thrombosis.   
The relation of MGP to blood vessels 
calcification is well known (see above). With 
respect to coagulation and thrombi formation, it can 
be suggested that MGP is somehow connected with 
these processes (Krueger et al., 2009). Such an 
assumption is based on the fact that MGP belongs 
to vitamin K-dependent proteins, a large number of 
which are procoagulants (prothrombin, factor V, 
etc) and can influence blood clotting and thrombi 
formation in the coronary and cerebral arteries. In 
some papers (Wallin et al., 2008), an antagonistic 
relationship between calcification and coagulation 
is discussed. Therefore, MGP can be considered as 
a connecting link between these two processes. 
Certainly, this assumption requires experimental as 
well as clinical proofs, and research in this 
direction should be continued.  
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